Antibodies Taken From Recovered Coronavirus Patient Could Yield Therapies
Lilly Partners With AbCellera
Executive Summary
Funded by the US government since March 2018, the Vancouver-based company aims to have an antibody therapy ready for clinical trials within four months.
You may also be interested in...
Coronavirus Hasn’t Sparked CURE ID Physician Social Network Interest
US FDA/NIH smartphone app is intended to allow clinicians and others to talk about potential treatments for infectious diseases, but so far COVID-19-related activity has been limited.
Fears Of Recession Mount As Coronavirus Declared A Pandemic
Investor sentiment still backing growth for pharma and biotech sectors, but the length and severity of COVID-19's impact globally has yet to be seen.
Sanofi To Test Arthritis Drug Kevzara For Coronavirus
The French giant is already working on a vaccine to combat COVID-19 and is now evaluating whether its rheumatoid arthritis drug Kevzara could treat pulmonary complications related to the coronavirus.